À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ¿¹Ãø(-2031³â) : Áö¿ªº° ºÐ¼®(ÄÄÆ÷³ÍÆ®º°, À¯Çüº°, »çÁöº°, ¿ëµµº°, À̵¿¼ºº°, ÃÖÁ¾ »ç¿ëÀÚº°)
Europe Medical Exoskeleton Market Forecast to 2031 - Regional Analysis - by Component, Type, Extremity, Application, Mobility, and End Users
»óǰÄÚµå : 1715173
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 117 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,873,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,285,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,698,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº 2023³â 1¾ï 748¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 8¾ï 5,396¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2023³âºÎÅÍ 2031³â±îÁö CAGR 29.6%·Î ÃßÁ¤µË´Ï´Ù.

³úÁ¹Áß°ú ±Ù°ñ°Ý°è Áõ°¡°¡ À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀ» °ßÀÎ

ÀÇ·á ¾÷°èÀÇ Áøº¸¿¡µµ ºÒ±¸Çϰí, ³úÁ¹ÁßÀº °øÁß º¸°Ç»óÀÇ Áß¿äÇÑ ¹®Á¦À̸ç, ³úÁ¹ÁßÀº »ç¸Á ¿øÀο¡¼­ ¼¼°è 2 À§ÀÌ¸ç ½Åü Àå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀ̱⵵ÇÕ´Ï´Ù. Global Stroke Factsheet 2022¿¡ µû¸£¸é ³úÁ¹ÁßÀ» ÀÏÀ¸Å°´Â Æò»ý À§ÇèÀº Áö³­ 17³â°£ 50% »ó½ÂÇßÀ¸¸ç, ÃßÁ¤ 4¸í Áß 1¸íÀÌ Æò»ý ¾îµò°¡¿¡¼­ ³úÁ¹ÁßÀ» °æÇèÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2¸¸°ÇÀÇ ³úÁ¹Áß ¹ßº´, 953¸¸¸íÀÇ ³úÁ¹Áß »ýÁ¸ÀÚ, 46¸¸¸íÀÇ ³úÁ¹Áß °ü·Ã »ç¸Á, 706¸¸³âÀÇ ³úÁ¹Áß¿¡ ÀÇÇÑ Àå¾Ö¿¡ ÀÇÇÑ »ý¸í »ó½ÇÀÌ ÀÖ¾ú½À´Ï´Ù. ³ª¶ó¿¡ µû¸¥ Â÷ÀÌ´Â ¾ÕÀ¸·Îµµ Á¸ÀçÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ƯÈ÷ µ¿À¯·´¿¡¼­´Â Áõ·Ê °ü¸®¿Í ¿¹¹æÀÇ Áøº¸ °¡´É¼ºÀ» ³ªÅ¸³»°í ÀÖ½À´Ï´Ù.

°Ô´Ù°¡ ±Ù°ñ°Ý°èÀÇ Àå¾Ö´Â °³ÀÎÀÇ ¿îµ¿ ´É·Â¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ ¿Ü°ñ°ÝÀº ȯÀÚÀÇ ÅëÁõ °ü¸®¸¦ µ½´Â °Í»Ó¸¸ ¾Æ´Ï¶ó ¿îµ¿ ´É·ÂÀÇ È¸º¹À» µ½°í ±×¿¡ µû¶ó ÀüüÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½Ãŵ´Ï´Ù.

À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå °³¿ä

À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ªÀº ¼¼°èÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ¾î ÁÖ¸ñÇØ¾ß ÇÒ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ³ª¶ó ½ÃÀå ±â¾÷Àº ½ÃÀå È®´ë¿Í ¼ºÀåÀ» À§ÇØ ÆÄÆ®³Ê½Ê ¹× Çù¾÷°ú °°Àº ¹«±â ¼ºÀå Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. 2022³â 8¿ù, German Bionic(½º¸¶Æ® ÆÄ¿ö ½´Æ® °³¹ßÀÇ ¼¼°èÀû ±â¼ú ¸®´õ)¿Í Mubea(µ¶ÀÏÀÇ Åé ÀÚµ¿Â÷ °ø±ÞÀÚ)°¡ Çù·Â ÇùÁ¤À» ü°áÇß½À´Ï´Ù. ¼¼°è ÃÖ°íÀÇ ·Îº¿ ¿Ü°ñ°Ý °³¹ß ±â¾÷ÀÇ »ý»êÀ» Áö¿øÇÔÀ¸·Î½á Mubea´Â ¹Ì·¡¿¡ ¸Å¿ì À¯¸ÁÇÑ ½ÅºÐ¾ß¸¦ °³Ã´Çß½À´Ï´Ù. À¯»çÇϰÔ, 2020³â 4¿ù, ReWalk Robotics Ltd.´Â µ¶ÀÏÀÇ ÃÖ°í ¹ýÁ¤ º¸Çè ȸ»ç("SHI"), Deutsche Angestellten-Krankenkasse-Gesundheit("DAK-Gesundheit"), Techniker Krankenkasse("TK")¿ÍÀÇ ±¹³» ÇùÁ¤À» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÇÕÀǸ¦ ÅëÇØ ô¼ö ¼Õ»óÀÚ¶ó¸é ´©±¸³ª ReWalk 6.0 ¿Ü°ñ°Ý ½Ã½ºÅÛÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. TK¿Í DAK´Â °¢°¢ µ¶ÀÏ¿¡¼­ 1,060¸¸ ¸í°ú 560¸¸ ¸íÀÇ ¼öÇýÀÚ¸¦ ´ëÇ¥ÇÏ¸ç µ¶ÀÏ¿¡¼­ °¡Àå Å« SHI Áß 2°³ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÇÕÀÇ´Â µ¶ÀÏ¿¡¼­ ¿Ü°ñ°Ý Á¶´ÞÀÇ Ç¥ÁØÀ» ¼³Á¤ÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀÇ ¼öÀͰú 2031³â±îÁöÀÇ ¿¹Ãø(±Ý¾× ±âÁØ)

À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀÇ ¼¼ºÐÈ­

À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ±¸¼º ¿ä¼Ò, À¯Çü, »çÁö, ¿ëµµ, À̵¿¼º, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ºÐ·ùµË´Ï´Ù.

ÄÄÆ÷³ÍÆ®º°·Î À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº Çϵå¿þ¾î¿Í ¼ÒÇÁÆ®¿þ¾î·Î ºÐ·ùµË´Ï´Ù. 2023³â À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­´Â Çϵå¿þ¾î ºÎ¹®ÀÌ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

À¯Çüº°·Î´Â À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº µ¿·Â½Ä ¿Ü°ñ°Ý°ú ¼öµ¿½Ä ¿Ü°ñ°ÝÀ¸·Î ±¸ºÐµË´Ï´Ù.

»çÁöº°·Î À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ÇÏ¹Ý½Å¿ë ¿Ü°ñ°Ý, »ó¹Ý½Å¿ë ¿Ü°ñ°Ý, Àü½Å¿ë ¿Ü°ñ°ÝÀ¸·Î ±¸ºÐµË´Ï´Ù.

¿ëµµº°·Î À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ô¼ö ¼Õ»ó, ´Ù¹ß¼º °æÈ­Áõ, ³úÁ¹Áß, ³ú¼º ¸¶ºñ, ÆÄŲ½¼º´ µîÀ¸·Î ±¸ºÐµË´Ï´Ù.

¸ðºô¸®Æ¼º°·Î À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº À̵¿½Ä ¿Ü°ñ°Ý°ú °ÅÄ¡Çü ¿Ü°ñ°ÝÀ¸·Î ±¸ºÐµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ÀçȰ¼¾ÅÍ, ¹°¸®Ä¡·á¼¾ÅÍ, Àå±â°£È£¼¾ÅÍ, ÀçÅð£È£ µîÀ¸·Î ±¸ºÐµË´Ï´Ù.

±¹°¡º°·Î À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù.

BIONIK, B-Temia Inc, Cyberdyne Inc, Ekso Bionics Holdings Inc, ExoAtlet, Hocoma AG, Lifeward, Inc, Myomo Inc, Rex Bionics Ltd., Wearable Robotics SR´Â À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºÐ¼® ¹æ¹ý

Á¦4Àå À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦5Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : À¯·´ÀÇ ºÐ¼®

Á¦6Àå À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ÄÄÆ÷³ÍÆ®º°

Á¦7Àå À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : À¯Çüº°

Á¦8Àå À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : »çÁöº°

Á¦9Àå À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦10Àå À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀÇ ºÐ¼® : ¸ðºô¸®Æ¼º°

Á¦11Àå À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦12Àå À¯·´ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦13Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ¾÷°è Á¤¼¼

Á¦14Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦15Àå ºÎ·Ï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Europe medical exoskeleton market was valued at US$ 107.48 million in 2023 and is expected to reach US$ 853.96 million by 2031; it is estimated to register a CAGR of 29.6% from 2023 to 2031.

Growing Incidence of Stroke and Musculoskeletal Drives Europe Medical Exoskeleton Market

Despite the advancements in the medical industry, stroke continues to be a major public health issue. Stroke ranks second in the world in terms of causes of mortality and is the main cause of disability. According to the Global Stroke Factsheet 2022, the lifetime risk of having a stroke has risen by 50% in the past 17 years, with an estimated 1 in 4 people expected to experience one at some point in their lives. Between 1990 and 2019, there was a rise of 70% in the incidence of stroke, 43% in the number of stroke-related deaths, 102% in the frequency of stroke, and 143% in Disability Adjusted Life Years (DALY). The most notable aspect is that lower- and lower-middle-income countries account for the majority of the world's stroke burden (86% of stroke-related fatalities and 89% of DALYs). In the European Union, there were 1.12 million stroke incidents, 9.53 million stroke survivors, 0.46 million stroke-related deaths, and 7.06 million years of life lost due to disability from stroke in 2017. Further, the number of people living with stroke is predicted to rise by 27% between 2017 and 2047, primarily as a result of aging populations and higher survival rates. It is anticipated that differences will continue to exist between nations, indicating potential for advancements in case management and prevention, especially in Eastern Europe. Therefore, the increasing incidences of stroke have boosted the demand for exoskeleton systems for rehabilitation of stroke patients to help improve the quality of life.

In addition, musculoskeletal disorders impact the mobility of an individual. The increasing prevalence of musculoskeletal disorders, such as tendinitis, osteopenia, sarcopenia, and low back injuries, result in a growing need for exoskeletan robotic systems. According to the World Health Organization (WHO), ~1.71 billion people globally are affected by musculoskeletal diseases, and lower back pain is a leading cause of disability in 160 countries. These exoskeletons assist patients in managing their pain, as well as help regain their mobility, thereby improving their overall quality of life. Thus, the increasing prevalence of stroke and musculoskeletal disorders has led to the use of exoskeletan robotic systems for rehabilitation.

Europe Medical Exoskeleton Market Overview

The European medical exoskeleton market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global medical exoskeleton market and is expected to register a notable CAGR. Market players in the country are adopting inorganic growth strategies such as partnerships and collaborations for market expansion and growth. In August 2022, German Bionic (a global technology leader in the development of smart power suits) and Mubea (the top German automotive supplier) entered a cooperation agreement. By assisting the world's top developer of robotic exoskeletons in production, Mubea tapped into a new and quite promising future sector. Similarly, in April 2020, ReWalk Robotics Ltd. announced the national agreement with top German Statutory Health Insurers ("SHI"), Deutsche Angestellten-Krankenkasse - Gesundheit ("DAK-Gesundheit"), and Techniker Krankenkasse ("TK"). This agreement can permit any eligible beneficiary with a spinal cord injury to get a ReWalk 6.0 exoskeleton system. TK and DAK, representing 10.6 million and 5.6 million beneficiaries in Germany, respectively, are two of the largest SHIs in the country; these agreements are expected to help set the standard for exoskeleton procurement in Germany.

Europe Medical Exoskeleton Market Revenue and Forecast to 2031 (US$ Million)

Europe Medical Exoskeleton Market Segmentation

The Europe medical exoskeleton market is categorized into component, type, extremity, application, mobility, end users, and country.

By component, the Europe medical exoskeleton market is bifurcated into hardware and software. The hardware segment held a larger share of the Europe medical exoskeleton market share in 2023.

In terms of type, the Europe medical exoskeleton market is bifurcated into powered exoskeleton and passive exoskeleton. The powered exoskeleton segment held a larger share of the Europe medical exoskeleton market share in 2023.

Based on extremity, the Europe medical exoskeleton market is segmented into lower body exoskeleton, upper body exoskeleton, and full body exoskeleton. The lower body exoskeleton segment held the largest share of the Europe medical exoskeleton market share in 2023.

By application, the Europe medical exoskeleton market is segmented into spinal cord injury, multiple sclerosis, stroke, cerebral palsy, Parkinson's Disease, and others. The spinal cord injury segment held the largest share of the Europe medical exoskeleton market share in 2023.

In terms of mobility, the Europe medical exoskeleton market is bifurcated into mobile exoskeleton and stationary exoskeleton. The powered exoskeleton segment held a larger share of the Europe medical exoskeleton market share in 2023.

By end users, the Europe medical exoskeleton market is segmented into rehabilitation centers, physiotherapy centers, long term care centers, homecare settings, and others. The rehabilitation centers segment held the largest share of the Europe medical exoskeleton market share in 2023.

Based on country, the Europe medical exoskeleton market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany segment held the largest share of Europe medical exoskeleton market in 2023.

BIONIK; B-Temia Inc; Cyberdyne Inc; Ekso Bionics Holdings Inc; ExoAtlet; Hocoma AG; Lifeward, Inc; Myomo Inc; Rex Bionics Ltd.; and Wearable Robotics SR are some of the leading companies operating in the Europe medical exoskeleton market.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Europe Medical Exoskeleton Market - Key Market Dynamics

5. Medical Exoskeleton Market - Europe Analysis

6. Europe Medical Exoskeleton Market Analysis - by Component

7. Europe Medical Exoskeleton Market Analysis - by Type

8. Europe Medical Exoskeleton Market Analysis - by Extremity

9. Europe Medical Exoskeleton Market Analysis - by Application

10. Europe Medical Exoskeleton Market Analysis - by Mobility

11. Europe Medical Exoskeleton Market Analysis - by End Users

12. Europe Medical Exoskeleton Market - Country Analysis

13. Medical Exoskeleton Market - Industry Landscape

14. Company Profiles

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â